ISPOR CEO Named a 2018 PharmaVOICE 100 Honoree

Published Aug 6, 2018
Nancy S. Berg Recognized as a Transformational Commander and Chief Lawrenceville, NJ, USA—August 6, 2018—ISPOR, the professional society for health economics and outcomes research, announced that CEO and Executive Director Nancy S. Berg has been named a 2018 PharmaVOICE 100 honoree by PharmaVOICE magazine. She has been recognized as a transformational leader in the Commander and Chief category. In 2014, Ms Berg moved into the role of CEO for ISPOR, the leading global scientific and educational organization for HEOR. Since that time, she has worked closely with ISPOR’s Board of Directors to strengthen the Society and further its mission to advance HEOR excellence to improve decision making globally. Ms Berg has initiated a number of key strategic initiatives during her tenure at ISPOR. After hiring the Society’s first ever Chief Science Officer, ISPOR began initiatives on value assessment frameworks and a jointly led initiative on real-world evidence (in partnership with the International Society for Pharmacoepidemiology). The Society launched its Health Technology Assessment Central, an online source that is a comprehensive repository of resources and tools to support health technology assessment. ISPOR is currently launching phase I of its comprehensive information technology (IT) initiative. The IT project includes a number of critical, integrated systems to better serve its global membership, such as an association management system and new website. Other key programs have included the initiation of a new Patient Council, an HEOR Competencies Framework™, and a Women in HEOR Initiative. The PharmaVOICE 100 was established fourteen years ago by PharmaVOICE magazine and is an annual list of inspirational individuals recognized for their positive contributions to the life sciences industry.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg ABOUT PharmaVOICE Published monthly, with the combined July/August PharmaVOICE 100 and November/December Year in Preview issues, PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of the executives who are shaping the direction of the dynamic and multifaceted life-sciences industry. PharmaVOICE reaches more than 46,000 BPA qualified subscribers and 60,000 users with its digital edition.

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×